Purpose: Data of the 2 more recent French LMB and German-Austrian-Switzerland-Czech NHL-BFM studies were pooled to analyse and compare their results. In LMB, patients are stratified in 3 risk groups (A, B, C) depending on resection, stage and CNS involvement, and receive 2, 4/5 or 8 courses of chemotherapy. In BFM, patients are stratified in 4 groups (R1, R2, R3, R4) adding LDH level in the stratification and receive 2, 4, 5 or 6 courses. Although treatment schemes and drug dosages are different in the 2 regimens, drugs are the same: high dose methotrexate, corticosteroid, vincristine, cyclophosphamide (+/-ifosfamide), ara-C (HD in advanced stages (st)), doxorubicine, and +/-VP16. Method: Data of the BFM 95 (Blood 2005), the ongoing 04 studies, the SFCE part of the FABLMB 96 (Blood 2007, BJH 2008 and the ongoing LMB 2001/03 studies were merged. Results: There were 935 patients in the BFM (04/96-12/05) and 691 patients in the LMB (07/96-12/05) studies, and a total of 42 PMLBL. For the non PMLBL results are given for BFM and LMB in this order. 4y EFS was 89% (n=914) and 90% (n=670) respectively. By st, 4y EFS was: 97% (n=96) and 98% (n=58) for st1, 98% (n=228) and 96% (n=114) for st2, 88% (n=373) and 92% (n=285) for st3, 76% (n=71) and 85% (n=87) for st4, 81% (n=146) and 81% (n=126) for B-AL, 72% and 79% for the CNS+. For the higher risk patients, defined as st3 with high LDH level (>500 inBFM or >twice the upper normal value in LMB), st4 or B-AL, 4y EFS was 83% (n=406) and 85% (n=366). All results were NS. Conclusion: These 2 regimens developed in parallel since 1981 using same drugs obtain similar results. This encourages an international collaboration, especially addressing the question of rituximab in higher risk patients.
Introduction/Background: The FAB/LMB96 trial demonstrated the safe reduction of chemotherapy intensity in C+A with intermediate risk Stage III/IV B-NHL (2 yr EFS 84%) (Patte/Cairo et al, Blood, 2007) . R has significantly improved EFS and OS in adults with DLBCL (Coiffier et al, NEJM, 2002) . Dose dense R dosing has been shown to result in sustained levels of R (Zwick et al, Semin Hematol, 2010) while demonstrating effective responses when compared to R dosed every 21 days (Habermann et al, J Clin Oncol, 2006) . A recent murine model demonstrated an inverse relationship between tumor burden and R concentration (Dayde et al, Blood, 2009 ) suggesting pediatric B-NHL patients, who frequently present with high tumor burden, may benefit from a dose dense approach. The study objective was to determine PK and safety following addition of R to FAB B4 chemotherapy in a dose dense manner in C+A with Stage III/IV mature B-NHL. Material/Methods: R (375mg/m 2 ), generously supplied by Genentech, was administered to patients with Stage III/IV mature B-NHL receiving FAB B4 chemotherapy. Subpilot patients received R (4 doses) on days -2 and 0 of COPADM2 and day 0 of CYM 1+2. Pilot patients also received R on days -2 and 0 of COPADM1 (6 doses). In a subset of patients, serum R levels were measured by ELISA using a polyclonal goat anti-R antibody conjugated to horseradish peroxidase (detection limit 0.5lg/mL) 1h prior (trough) and 30-60min after (peak) each R dose in COPADM 1+2 as well as 1, 3, 6 and 9 mo after the last R dose for estimating t½. Results: Forty-eight patients received 274 R infusions. No SAE attributed to R occurred and no HACA were detected. PK samples were obtained for 22 patients. Serum R levels were as reported in Table 1 . The t½ of R was 29±7 days. Younger children (age <13y) demonstrated higher peak values but similar trough levels and a shorter t½. Conclusion: R can be safely added to FAB B4 chemotherapy with R peak/trough levels and t½ similar to those seen in adults. A dose dense approach can be safely utilized to achieve high R peak levels with sustained troughs despite high tumor burden. Our results also suggest younger children tend to achieve higher R peaks with a higher rate of clearance supporting the continued use of BSA based R dosing in pediatrics. OS=89,9±3,8%, EFS=85,9±4,0%; B-ALL: OS=53,6±12,3%' EFS=40,2±12,4%), comparing to results reported by BFM (NHL-B + B-ALL: EFS=0,89%, B-ALL: EFS=0,81%) and LMB (NHL-B + B-ALL: EFS=0,90%, B-ALL: EFS=0,81%).
Since 2004, 131 pts were enrolled in the protocol, including 78 with Burkitt lymphoma (60%), 19 with DLBCL (15%), 2 with PMLBCL (1%), 20 with B-ALL (15%) and 12 with others (9%). The predominant primary site of the disease was abdomen -51 (39 %) pts. 73% of patients presented with localized disease: st I -5 (4%), st II -29 (22%), st III -61(47%) and 27% with disseminated disease: st IV -19 (14%) and B-ALL -17 (13%). CNS involvement was diagnosed in 9 (7%) cases. Pre-treatment high LDH level was found in 57 (43%) cases. Pts were stratified in the following treatment groups: R1 -2 (1%), R2 -48 (37%), R3 -26 (20%), R4 -55 (42%).
CR was achieved in 103 patients (79%), 12 (60%) patients with B-ALL and 91 (82%) with NHL-B. Six patients (6%) relapsed -four with B-ALL, one with Burkitt lymphoma and one with PMLBCL. There were four isolated relapses (two CNS, one mediastinal, one testicular) and two with bone marrow involvement. In three cases of isolated relapses remission was achieved. Patients remain in RC (3 y, 2 y and 6 months respectively).
There were 15 deaths reported (11%) -seven in the NHL-B group and eight in B-ALL group. The main cause of death was lack of response to treatment (6 pts/4,5%); the other causes were the following: infectious complications (3 pts/3%), relapses (3 pts/3%), iatrogenic complications (venous thrombosis and pulmonary embolism post central catheterisation) (1pt/1%), late complications after completion of therapy (1pt/1%).
It seems that the main cause of treatment failure is a high number of patients not responding to chemotherapy. This group consists mostly of patients diagnosed with B-ALL and primary large tumor mass. It appears advisable to distinguish these patients as very high risk group, determine new prognostic factors for this group and establish more aggressive treatment. Background: The IPI predicts outcome in aggressive lymphoma (aNHL); age > 60 yrs is a strong prognostic factor. It is not known if the age-dependen risk for OS (overall survival) and EFS (event free survival) increases in pts aged between 18 and 60 yrs. Adolescent pts are frequently treated with paediatric-type protocols, inducing a supposedly better outcome. However, biological differences such as the different proportion of non-mBL vs mBL (molecular Burkitts index) pts and genetic aberrations in different age groups (Klapper et al, 2009 ) may also account for these differences. In order to gain more insight into the age difference of outcome in young a NHL patients (pts), data from prospective trials of the DSHNHL were analyzed with a focus on agedependent outcome. Materials/Results: Patient data (age 18-60, n=2151) were retrieved from the following published DSHNHL trials: NHL-B1 (n=710,<60, LDH normal), MINT (n=821, IPI 0/ 1), High CHOEP phase II (n=119) and phase III (n=389, IPI 0/1), Mega CHOEP phase II (n=110, LDH elevated). 524 pts were < 35 yrs old. OS and EFS were calculated in pts 18-20 yrs (9.4%), and in 5-yr intervals > 20 yrs (21.6%, 31.9%, 37.2%). 82.4% had B cell histology. Mediastinal localization occured in 42% of pts <35 yrs. Treatment was CHOP/CHOEP based, rituximab was used in MINT only. In a multivariate analysis in NHLB1 pts < 35 yrs, stage III/IV (RR 3.4), ECOG>1 (RR 4.1) and etoposide use (RR 0.4) were significant risk factors, but none of the different age groups. This was similar for the other trials, and bulky disease was a risk factor in MINT. A larger dataset of 4165 pts aged 18-75 yrs was employed for a similar analysis, demonstrating that age dependent risk for similar IPI groups increases at age 50 approx. A martingale residual analysis in this cohort demonstrated that the risk for OS starts to increase at 45+ yrs, and the risk for EFS increases monotonously at 55+ yrs. Conclusions: Outcome in all low-risk pts < 50 yrs is excellent with CHOP based protocols, with approx 90% OS @ 40 mths, and there is no difference in outcome between pts aged 18-20, 21-25, 26-30 and 31-40 yrs. Risk-dependent outcome seems similar to adolescent pts treated with paediatric protocols, e.g. in mediastinal lymphoma. Age dependent risk increases around 50 yrs of age. A matched pair analysis w/ paediatric-type treated pts, including biological risk factors as well as more rituximab data is warranted.
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More than 15 different anaplastic lymphoma kinase (ALK) fusions (e.g., CLTC-ALK, multiple EML4-ALK variants, KIF5B-ALK, NPM-ALK, RanBP2-ALK, SEC31A-ALK, TFG-ALK, TPM4-ALK, and others) are now known to cause subsets of various malignancies including NHL (anaplastic large-cell lymphoma [ALK+ ALCL], diffuse large B-cell lymphoma [ALK+ DLBCL]), inflammatory myofibroblastic tumor (IMT), and non-small cell lung cancer (NSCLC). In addition, preliminary studies suggest that subsets of several other cancers may also express oncogenic ALK fusions that drive their development (e.g., breast, colorectal and esophageal cancers). Furthermore, point mutations that constitutively activate ALK have been identified as driver mutations in the pediatric malignancy neuroblastoma. Given the large variety of cancers caused by ALK deregulation, a number of pharmaceutical and biotech companies have ALK small-molecule inhibitors in development. Patients with ALKdriven cancers such as NSCLC and IMT treated with the ALK inhibitor PF-02341066 (crizotinib, Pfizer), which is currently in registration trials, have had marked antitumor responses including occasional complete remissions, indicating that these tumors are truly ''addicted'' to ALK. Preclinical ALK+ lymphoma models have demonstrated exquisite antitumor sensitivity to small-molecule inhibitors of the kinase, including apparent cures of even systemic lymphomatous involvement with ALK inhibitor monotherapy. To date, only a handful of ALK+ NHL patients have been treated with crizotinib but the responses reported in these few patients have also been quite marked, especially given that these are patients with lymphomas that have failed conventional therapies. Trials of crizotinib have recently begun recruitment of ALK+ NHL patients; thus, the efficacy of this ALK inhibitor in a controlled experimental clinical setting will soon be known. The availability of crizotinib -and of 2nd-generation ALK smallmolecule inhibitors that are entering the clinic as well -promises to revolutionize the treatment of ALK+ NHL. However, considerable work will be required to determine the most beneficial role for such therapy including its timing, the preferred combination(s) of ALK inhibitors with conventional therapies, and the optimal strategy to combat the emergence of inhibitor resistance. Dr. Morris will present background regarding ALK and its pathogenic role in human cancers, an update on the current status of ALK inhibitor development, and will speculate as to the ultimate role for these inhibitors in the therapy of patients with ALK+ lymphomas. Introduction/Background: Autoantibody responses to the anaplastic lymphoma kinase (ALK) oncoantigen have been described in patients with nucleophosmin (NPM)-ALK positive anaplastic large cell lymphoma (ALCL). These antibody titres could be correlated with the risk of relapse (Ait-Tahar et al, Blood 2010). We now asked whether the presence of circulating ALK-specific antibodies was limited to patients with NPM-ALK-positive ALCL or could also be detected in those patients with ALK-positive ALCL or diffuse large B-cell lymphoma (DLBCL) patients whose tumours expressed variant ALK fusion partners. Material and methods: 77 tumours from patients with the reference diagnosis of ALKpositive ALCL and 2 ALK-positive DLBCL were screened for the presence of NPM-ALK fusion by a NPM-ALK-specific RT-PCR technique or by fluorescence in situ hybridisation. Eleven patients lacked a detectable NPM-ALK fusion. Immunohistochemically, all displayed a characteristic cytoplasmically restricted ALK-staining pattern. The presence and magnitude of ALK-specific antibodies in their sera were analysed as previously described (Pulford et al, Blood 2000) . Results: The tumour cells of the 11 ALK-positive lymphoma-patients expressed the following variant ALK fusion partners: 9 ALCL with 2 ATIC-ALK, 1 MYH9-ALK, 3 TPM3-ALK, 3 variant ALK-partners not further classified; 2 plasmoblastic DLBCL with CLTC-ALK. Eight of the 9 patients with ALK-positive ALCL mounted an antibody response against ALK with titres ranging from 1/100 to 1/60750. No ALK autoantibodies were detected in the patient with the MYH9-ALK fusion. ALK-specific antibodies were detected in 1 of the 2 patients with CLTC-ALK positive DLBCL (titre: 1/6750). The 2 ALCL patients who relapsed among 8 patients with sufficient follow-up had low anti-ALK titres (1/100, 1/750). The DLBCL-patient with antibody response progressed during therapy.
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